

ASX ANNOUNCEMENT

**Allied Healthcare announces the patent for the ADAPT[®]-TEP process
has been granted for Singapore.**

Brisbane, Australia, 19 March 2012

Allied Healthcare Group (ASX: AHZ) announced today its tissue engineering and regenerative medicine division Celxcel has received confirmation that its ADAPT[®]-Tissue Engineering Process (TEP) patent has successfully been granted in Singapore.

"This continues to grow the overall family of patents in key markets for the ADAPT[®]-TEP platform technology" said Lee Rodne, Managing Director, Allied Healthcare Group.

The granting of the Singaporean patent for the ADAPT[®]-TEP process adds to the existing granted patents in many jurisdictions including Australia, New Zealand and China. The technology is protected by patent filings globally, including the USA, Europe, Japan, Israel and Canada.

"The Celxcel technology has a robust patent position around our current platform technology (ADAPT[®]-TEP) and we continue to pursue filings to cover our future portfolio of products," said Bob Atwill, CEO of Celxcel. "This granted patent is another example of the fruits of our endeavors in this area".

The ADAPT[®]-TEP process is a technology platform which has been used across a number of tissue types for use in cardiovascular, pelvic floor reconstructions and hernia repair applications. Celxcel is also evaluating how the process can be used in orthopaedics and as a biological scaffold to grow and deliver stem cells.

For more information, please contact:

Dr Julian Chick, Chief Operating Officer Allied Healthcare Group Tel: +61 8 9266 0100
Bob Atwill, Allied Healthcare Group Executive and Celxcel CEO Tel: +61 448 778 880

Media:

Paul Dekkers
Buchan Consulting
+61 2 9237 2800
pdekkers@buchanwe.com.au



About Allied Healthcare Group Limited

Allied Healthcare Group Limited (ASX: AHZ) is a diversified healthcare company focused on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow its product and service offerings and expanding revenues from its existing profitable medical sales and distribution business. The Company has assets from Research & Development through Clinical Development as well as Sales, Marketing and Distribution.

Allied Healthcare Group is in the process of commercializing its innovative tissue engineering technology for regenerative medicine and is a major investor in Brisbane based Coridon Pty Ltd, led by Professor Ian Frazer developing next generation vaccines for global markets.

Further information on the Company can be found on www.alliedhealthcaregroup.com.au.

About Celxcel

Celxcel, a regenerative tissue engineering technology company founded in 2001 focusing on tissue engineering and regenerative medicine based around the proprietary ADAPT® Tissue Engineering Process (TEP). Celxcel's lead program has successfully completed a number of preclinical studies and a Phase II human clinical trial for its lead product CardioCel®. CardioCel® is a cardiovascular patch used to repair and treat paediatric heart deformities ranging from routine "Hole in the Heart" operations to major vessel outflow tract repairs and valve reconstructions in paediatric patients.

Celxcel uses its patented ADAPT® Tissue Engineering Process (TEP) as a platform technology to produce implantable tissue patches for use in various soft tissue repair applications and for the production of replacement tissue heart valves. The ADAPT® technology is used to process animal derived tissues to produce implantable tissue patches that are compatible with the human body. The technology has a number of advantages over current tissue treatment processes on the market, most notably the reduction of calcification post implantation. The technology has the potential for medical professionals to use regenerative products instead of synthetic products currently used in soft tissue repair.

About the ADAPT® Tissue Engineering Process

ADAPT® Tissue Engineering Process (TEP) produces a bioprosthetic scaffold (extracellular matrix) made from animal tissue. Depending on the site of implantation, the patient's own cells will migrate into the matrix and stimulate site specific controlled remodelling. At the same time, new blood vessels are formed in the matrix and they deliver appropriate cells that lead to a functional tissue repair. The implanted extracellular matrix is gradually remodelled and replaced by the body's own new tissue structures.



ABN 35 088 221 078

Level 1, 197 Adelaide Terrace
Perth Western Australia 6000

PO Box 6879 East Perth
Western Australia 6892

T +61 (0)8 9266 0100

F +61 (0)8 9266 0199

E info@alliedhealthcaregroup.com.au

www.alliedhealthcaregroup.com.au